Join us for Barth Syndrome Foundation’s virtual townhall on May 23rd at 12pm ET to learn more about the valuable role that the worldwide Barth syndrome community will play in the FDA’s review of Stealth’s new drug application (NDA) for elamipretide.

As a part of the FDA’s review, the Barth Syndrome Foundation anticipates that the FDA’s Cardiovascular and Renal Drugs Advisory Committee will convene a meeting in 2024 to recommend to the FDA whether the drug should be approved for use by people living with Barth syndrome. This Advisory Committee meeting will be a critical opportunity for the personal experiences of our global community to be heard and weighed in the regulatory decision-making process.

Barth families, friends, healthcare providers, and all concerned and interested advocates are welcome and encouraged to attend.